

| | |
|--------------------------------------|---|
| NHS Greater Glasgow and Clyde | Paper No. 25/144 |
| Paper Title | Standing Committee Chairs Board Report |
| Meeting: | NHSGGC Board Meeting |
| Date of Meeting: | 30 October 2025 |
| Purpose of Paper: | For Assurance |
| Classification: | Board Official |
| Name of Reporting Committee: | Clinical and Care Governance Committee |
| Date of Reporting Committee: | 4 September 2025 |
| Committee Chairperson: | Dr Paul Ryan, Chair of the Committee |

1. Purpose of Paper:

The purpose of this paper is to inform the NHS Board on key items of discussion at the Clinical and Care Governance Committee.

2. Recommendation:

The Board is asked to note the key items of discussion at the recent meeting of the Clinical and Care Governance Committee on Thursday 4 September 2025 as set out below and seek further assurance as required.

3. Key Items of Discussion

3.1 Fatal Accident Inquiries Update

- The paper was presented to the Committee for awareness.
- The Committee was provided with an update on the FAIs that had been escalated by the Inquiries Oversight Sub Committee to ensure appropriate oversight, learning and governance.
- The Committee was assured by the update.

3.2 Skye House Update

- The Committee received a presentation for awareness.
- The Committee was provided with an overview of the current position with regards to Skye House and noted the ongoing scrutiny and assurance work. The Committee was also advised that an Executive Oversight Group was in place.
- The Committee was assured by the update.

3.3 Acute Services Clinical Governance Update – Exception Report

- The paper was presented to the Committee for assurance.
- The Committee was provided with an update on progress and activity within acute services setting out the key successes over the year as well as the key areas of challenge and risk and an overview of the cross-system learning. The Committee noted the work that had been undertaken across the system to support EDs and Unscheduled Care performance.
- The Committee was assured by the update.

3.4 Primary and Community Care Clinical Governance Update – Full Report

- The paper was presented to the Committee for assurance.
- The Committee was provided with an update on progress and activity within primary and community care services setting out the key successes over the year as well as the key areas of challenge and risk. The Committee was also provided with an overview of the cross-system learning which included the pregnancy prevention programme associated with topiramate prescribing and the digital dermatology app.
- The Committee was assured by the update.

3.5 Care Homes Update

- The paper was presented to the Committee for assurance.
- The Committee received an update on the continued development of the Care Homes Support Model across the six HSCPs highlighting the impact of the Collaborative Care Home Support Teams and the Care Home Collaborative in supporting the delivery of high quality patient care. The Committee was also advised of the key achievements which included strengthening of governance arrangements, the culture of shared learning and continuous improvement as well as a number of quality improvement initiatives which had delivered good outcomes.
- The Committee was assured by the update.

3.6 Assurance Information Framework KPIs – Safety and Quality programmes

- The paper was presented to the Committee for awareness.
- The Committee received an update on the Safety and Quality Programme Key Performance Indicators (KPIs) aligned to the Committee including details on the rate of Acute inpatient falls, the rate of cardiac arrests per 1,000 discharges and the Hospital Standardised Mortality Ratio in Acute hospitals as well as an update on the Improvement Programmes aligned to these areas.
- The Committee was assured by the update.

3.7 Healthcare Associated Infection Reporting Template (HAIRT)

- The paper was presented to the Committee for assurance.

- The Committee was advised that there were no exceptions to report and performance in NHSGGC was within control limits.
- Further narratives on targets had been included in the report, noting that there was an ongoing surveillance review in NHS Scotland. The Committee was also presented with a deep dive into the recent increase in CDifficile number that had been discussed at the previous meeting, noting that this had now reduced significantly and there had been no trends identified.
- The Committee was assured by the paper.

3.8 Significant Adverse Event Review (SAER) Update

- The paper was presented to the Committee for assurance.
- The Committee received an update on SAER activity performance and improvement and noted that the Interim Policy and Procedure for Managing Significant Adverse Events had been approved at the NHS Board Meeting on 24 June 2025. A rapid action plan had been developed which had made significant progress in reducing the number of potential and overdue SAERs.
- The Committee was assured by the paper.

3.9 Patient Experience Report – Quarter 1

- The paper was presented to the Committee for assurance.
- The Committee was advised that overall performance in the number of complaints responded to within 20 working days had seen a slight improvement despite a 2% increase in the number of complaints received. There continued to be good engagement through feedback and good progress on the person centred care strategy.
- The Committee was assured by the update.

3.10 Feedback, Comments, Concerns, Compliments and Complaints Annual Report 2024/25

- The paper was presented to the Committee for endorsement.
- The Committee noted that there had been a 7% increase in complaints since the previous year with an overall performance of 74% of Stage 1 and Stage 2 complaints closed within the timescale. The Committee noted that NHSGGC became the first NHS Board in Scotland to reach over 3,000 Care Opinion stories in one year, 78% of which had been positive.
- The Committee was content to endorse the report which would be presented to the NHS Board on 30 October 2025.

3.11 NHSGGC Clinical Governance Annual Report 2024-25

- The paper was presented to the Committee for endorsement.
- The Committee was advised that the main focus of the report was to provide assurance in relation to the management of clinical governance arrangements, as well as an overview of the activity undertaken during the year to provide high quality, person-centred care which was effective and safe. The Committee was also advised on improvement and good practice work that had taken place across the Board.
- The Committee was content to endorse the report which would be presented to the NHS Board on 30 October 2025.

3.12 NHSGGC Duty of Candour Annual Report 2024-25

- The paper was presented to the Committee for endorsement.

- The Committee was advised that there had been good compliance with the statutory regulations under Duty of Candour and noted that an addendum with updated figures would be brought to the Committee at a later date as there were investigations that remained ongoing.
- The Committee was content to endorse the report which would be presented to the NHS Board on 30 October 2025.

3.13 Public Protection Strategy Annual Update

- The paper was presented to the Committee for endorsement.
- The Committee received an update on the key actions, achievements and future priorities in safeguarding vulnerable populations and were assured by the multi-agency approaches, workforce development, quality assurance and the integration of digital solutions.
- The Committee was content to endorse the report which would be presented to the NHS Board on 30 October 2025.

3.14 West of Scotland Research Ethics Service Annual Report 2024-25

- The paper was presented to the Committee for endorsement.
- The Committee received an overview of the activities of the West of Scotland Research Ethics Service during the year 2024/25 noting the service's purpose, structure, functions and key activities, including information on the number of research applications that were reviewed during the year. The Committee was also provided with information on the challenges and developments for 2025/26 including the upcoming changes to clinical trial regulations and system processes and were assured by the preparations underway to ensure full compliance with this.
- The Committee was content to endorse the report which would be presented to the NHS Board on 30 October 2025.

3.15 Extract from the Corporate Risk Register

- The paper was presented to the Committee for approval.
- The Committee was advised that all risks had been reviewed with no proposed changes to scores.
- The Committee was content to approve the register.

4. Issues for referral to other Standing Committees or escalation to the NHS Board

There were no issues for referral to other Standing Committees or escalation to the NHS Board.

5. Date of Next Meeting

The next meeting of the Committee will take place on Thursday 4 December 2025.